Published in J Virol on November 01, 1999
Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci U S A (2004) 3.43
Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev (2008) 3.07
Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution. Proc Natl Acad Sci U S A (2003) 2.91
Identification of endogenous retroviral reading frames in the human genome. Retrovirology (2004) 2.58
Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol (2003) 2.31
Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology (2011) 1.80
CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol (2005) 1.72
Use of endogenous retroviral sequences (ERVs) and structural markers for retroviral phylogenetic inference and taxonomy. Retrovirology (2005) 1.46
HERV-K(HML-2), the Best Preserved Family of HERVs: Endogenization, Expression, and Implications in Health and Disease. Front Oncol (2013) 1.30
Rous sarcoma virus DR posttranscriptional elements use a novel RNA export pathway. J Virol (2000) 1.25
Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol (2007) 1.14
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J Virol (2012) 1.10
Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol (2004) 1.09
A retroviral promoter and a cellular enhancer define a bipartite element which controls env ERVWE1 placental expression. J Virol (2004) 1.07
The human endogenous retrovirus K Rev response element coincides with a predicted RNA folding region. RNA (2000) 1.04
Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology (2013) 0.96
Rec (formerly Corf) function requires interaction with a complex, folded RNA structure within its responsive element rather than binding to a discrete specific binding site. J Virol (2001) 0.95
ERV3 and related sequences in humans: structure and RNA expression. J Virol (2005) 0.94
Foamy virus envelope glycoprotein is sufficient for particle budding and release. J Virol (2003) 0.93
An element in the 3' untranslated region of human LINE-1 retrotransposon mRNA binds NXF1(TAP) and can function as a nuclear export element. RNA (2002) 0.93
Expression of the human endogenous retrovirus (HERV) group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by transcription factors Sp1 and Sp3. J Virol (2011) 0.93
Human endogenous retrovirus HERV-K(HML-2) encodes a stable signal peptide with biological properties distinct from Rec. Retrovirology (2009) 0.93
Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites. Retrovirology (2011) 0.93
Identification of the Rem-responsive element of mouse mammary tumor virus. Nucleic Acids Res (2008) 0.92
Presence of dUTPase in the various human endogenous retrovirus K (HERV-K) families. J Mol Evol (2003) 0.90
Gammaretrovirus mRNA expression is mediated by a novel, bipartite post-transcriptional regulatory element. Nucleic Acids Res (2014) 0.89
Identification of novel endogenous betaretroviruses which are transcribed in the bovine placenta. J Virol (2010) 0.88
Structural and functional analysis of the RNA transport element, a member of an extensive family present in the mouse genome. J Virol (2005) 0.87
Converging strategies in expression of human complex retroviruses. Viruses (2011) 0.86
Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening. Clin Vaccine Immunol (2011) 0.84
Human Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K-Related Sequences. J Virol (2015) 0.83
Staufen-1 interacts with the human endogenous retrovirus family HERV-K(HML-2) rec and gag proteins and increases virion production. J Virol (2013) 0.81
Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K. J Virol (2000) 0.80
HERV-K(HML-2) rec and np9 transcripts not restricted to disease but present in many normal human tissues. Mob DNA (2015) 0.80
Variant splicing and influence of ionizing radiation on human endogenous retrovirus K (HERV-K) transcripts in cancer cell lines. PLoS One (2013) 0.78
The bovine immunodeficiency virus Rev protein: identification of a novel nuclear import pathway and nuclear export signal among retroviral Rev/Rev-like proteins. J Virol (2012) 0.78
Modulation of human endogenous retrovirus (HERV) transcription during persistent and de novo HIV-1 infection. Retrovirology (2015) 0.77
Biochemical analysis of the complex between the tetrameric export adapter protein Rec of HERV-K/HML-2 and the responsive RNA element RcRE pck30. J Virol (2012) 0.77
"Reverse genomics" and human endogenous retroviruses. Trans Am Clin Climatol Assoc (2014) 0.75
CRM1 is an export receptor for leucine-rich nuclear export signals. Cell (1997) 18.60
CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature (1997) 10.49
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell (1995) 9.98
rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A (1989) 8.76
Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature (1997) 7.47
Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res (1998) 6.11
HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell (1990) 5.82
Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol (1990) 5.64
Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol (1997) 5.49
Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 5.47
The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol (1989) 5.07
The HIV-1 Rev protein. Annu Rev Microbiol (1998) 4.78
HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region. Cell (1990) 4.50
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A (1996) 4.48
The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol (1997) 4.35
Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome. J Virol (1986) 3.52
Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol (1997) 3.28
Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc Natl Acad Sci U S A (1991) 3.06
The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol Cell Biol (1992) 2.83
Nuclear export receptors: from importin to exportin. Cell (1997) 2.82
HIV-1 auxiliary proteins: making connections in a dying cell. Cell (1998) 2.68
Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A (1993) 2.43
Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. Virology (1993) 2.32
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J Virol (1991) 2.30
Molecular cloning and long terminal repeat sequences of human endogenous retrovirus genes related to types A and B retrovirus genes. J Virol (1986) 2.25
Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev (1990) 2.24
Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res (1990) 2.14
Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J Mol Biol (1997) 2.00
Identification of a Rev-related protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-K. J Virol (1995) 1.91
Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol (1994) 1.88
An almost-intact human endogenous retrovirus K on human chromosome 7. Nat Genet (1999) 1.87
Human teratocarcinomas cultured in vitro produce unique retrovirus-like viruses. J Gen Virol (1984) 1.36
Molecular biology of HIV-1: positive and negative regulatory elements important for virus expression. AIDS (1993) 1.27
Intracellular trafficking of the human immunodeficiency virus type 1 Rev protein: involvement of continued rRNA synthesis in nuclear retention. AIDS Res Hum Retroviruses (1995) 1.19
Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of human T-cell leukemia virus type 1. J Virol (1998) 1.13
Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses. Virology (1997) 1.11
Rex-dependent nucleolar accumulation of HTLV-I mRNAs. New Biol (1991) 1.07
Complete nucleotide sequence of the new simian T-lymphotropic virus, STLV-PH969 from a Hamadryas baboon, and unusual features of its long terminal repeat. J Virol (1997) 1.06
The HTLV-1 Rex protein induces nuclear accumulation of unspliced viral RNA by avoiding intron excision and degradation. Virology (1996) 1.04
Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element. J Virol (1992) 1.04
High-resolution mapping of the human T-cell leukemia virus type 1 Rex-binding element by in vitro selection. J Virol (1995) 0.96
The human immunodeficiency virus type 1 Rev protein: a pivotal protein in the viral life cycle. Curr Top Microbiol Immunol (1995) 0.90
HTLV-1 Rex protein accumulates unspliced RNA in the nucleus as well as in cytoplasm. Oncogene (1991) 0.89
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A (1996) 4.48
Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A (1993) 2.43
Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. Virology (1993) 2.32
Identification of a Rev-related protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-K. J Virol (1995) 1.91
DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer (1999) 1.86
Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang (2001) 1.53
Human teratocarcinomas cultured in vitro produce unique retrovirus-like viruses. J Gen Virol (1984) 1.36
HERV-K: the biologically most active human endogenous retrovirus family. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.26
Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med (1986) 1.18
Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1. AIDS (1991) 1.14
Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis (2009) 1.13
Hepatitis C transmission associated with intravenous immunoglobulins. Lancet (1995) 1.07
Endogenous D-type (HERV-K) related sequences are packaged into retroviral particles in the placenta and possess open reading frames for reverse transcriptase. Virology (1996) 1.04
AIDS: animal retrovirus models and vaccines. J Acquir Immune Defic Syndr (1988) 1.04
Structural organization of unique retrovirus-like particles budding from human teratocarcinoma cell lines. J Gen Virol (1983) 1.04
Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob Agents Chemother (1989) 1.03
Functional purification and enzymic characterization of the RNA-dependent DNA polymerase of human immunodeficiency virus. J Gen Virol (1986) 1.01
Expression of human endogenous retrovirus type K envelope glycoprotein in insect and mammalian cells. J Virol (1997) 1.01
Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine (2009) 0.99
Corf, the Rev/Rex homologue of HTDV/HERV-K, encodes an arginine-rich nuclear localization signal that exerts a trans-dominant phenotype when mutated. Virology (2000) 0.96
Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1. J Virol (1999) 0.96
HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett (1989) 0.96
Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster. Int J Clin Pharmacol Ther (2007) 0.95
Rec (formerly Corf) function requires interaction with a complex, folded RNA structure within its responsive element rather than binding to a discrete specific binding site. J Virol (2001) 0.95
Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K. Cell (1998) 0.94
[First exchange of experiences concerning the H1N1 pandemic in Germany 2009/2010: report on a workshop held March 22-23, 2010, in Berlin]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2010) 0.93
A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol (1999) 0.93
Conservation and loss of the ERV3 open reading frame in primates. Genomics (2004) 0.90
Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3'-azido-3'-deoxythymidine triphosphate. Antimicrob Agents Chemother (1988) 0.89
Insufficient inactivation of HIV-1 in human cryo poor plasma by beta-propiolactone: results from a highly accurate virus detection method. Biologicals (1993) 0.86
Oligonucleotide and plasmid DNA packaging into polyoma VP1 virus-like particles expressed in Escherichia coli. Biotechnol Appl Biochem (1999) 0.85
Phosphorylating proteins as effectors in malignant cell transformation. Adv Cyclic Nucleotide Res (1981) 0.84
Rapid evaluation and optimization of recombinant protein production using GFP tagging. Protein Expr Purif (2001) 0.84
Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine (1995) 0.83
Heterophil human antibodies recognize oncovirus envelope antigens: epidemiological parameters and immunological specificity of the reaction. Virology (1981) 0.82
The harmonization of the regulation of blood products: a European perspective. Vox Sang (2008) 0.82
Serum and serum substitutes: virus safety by inactivation or removal. Dev Biol Stand (1999) 0.82
Quantitative determination of N epsilon-methylated lysines in human plasma and urine. Hoppe Seylers Z Physiol Chem (1973) 0.81
Retrovirus particle production in three of four human teratocarcinoma cell lines. Haematol Blood Transfus (1981) 0.80
Detection and characterization of betaretroviral sequences, related to sheep Jaagsiekte virus, in Africans from Nigeria and Cameroon. Virology (2004) 0.80
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs. J Antimicrob Chemother (1988) 0.79
[N epsilon-methylated lysine: degradation and excretion]. Hoppe Seylers Z Physiol Chem (1972) 0.79
Causality assessment of suspected virus transmission by human plasma products. Transfusion (2001) 0.79
Hepatitis C virus antibody prevalence among human immunodeficiency virus-1-infected individuals: analysis with different test systems. J Med Virol (1994) 0.79
Comparison of radioimmunoprecipitation assays for the detection of human anti-tumor virus antibodies. J Immunol Methods (1979) 0.79
Frequencies of GB virus C/hepatitis G virus genomes and of specific antibodies in German risk and non-risk populations. J Med Virol (1997) 0.78
High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS (1991) 0.78
[Improved column chromatographic determination of N methylated lysine in physiological solutions]. J Chromatogr (1973) 0.78
Safety issues for plasma derivatives and benefit from NAT testing. Biologicals (1999) 0.77
Human T-cell lymphocytotrophic virus prevalence in German blood donors and "at-risk" groups. Vox Sang (2001) 0.77
Synthesis of retrovirus-like particles in testicular teratocarcinomas. J Urol (1982) 0.76
Spontaneous obesity-linked type 2 diabetes in the absence of islet amyloid in a cynomolgus monkey infected with bovine spongiform encephalopathy. Vet Pathol (2013) 0.76
Prevalence of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation. Clin Ther (1996) 0.76
Cold-attenuated live influenza vaccines, a risk-benefit assessment. Vaccine (2001) 0.75
Functional analysis of the env open reading frame in human endogenous retrovirus IDDMK(1,2)22 encoding superantigen activity. J Virol (2000) 0.75
Epidemiology and pathogenicity of human retroviruses. Dev Biol Stand (1991) 0.75
[HIV: virology and vaccination]. Verh Dtsch Ges Inn Med (1988) 0.75
Detection of antibodies to HTLV-III in commercially available immunoglobulin preparations. Klin Wochenschr (1986) 0.75
Detection of a point mutation in poliovaccines with a water soluble carbodiimide reaction of DNA heteroduplexes. Dev Biol Stand (1996) 0.75
[Early summer meningoencephalitis vaccination. The indications and a critical assessment of the neurological vaccination complications]. Dtsch Med Wochenschr (1992) 0.75
Retroviruses in human tumors. Arch Geschwulstforsch (1983) 0.75
[Eosinophilic myocarditis in Churg-Strauss syndrome. A rare cause of left heart decompensation with lung edema]. Dtsch Med Wochenschr (2000) 0.75
Hepatitis B virus polymerase chain reaction--a possible alternative method to the in vivo assay using chimpanzees. Dev Biol Stand (1996) 0.75
Human T-cell lymphotropic virus antibody screening: data survey on 33,603 German blood donors correlated to confirmatory tests. Vox Sang (1985) 0.75
Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals (1999) 0.75
Theoretical considerations on viral inactivation or elimination. Dev Biol Stand (1993) 0.75
Influence of additional methyl groups in the N-epsilon-amino position of lysine on the renal handling. Pflugers Arch (1974) 0.75
Diagnostic meaning of the urinary output of Nepsilon-methylated lysines. Investigation of healthy individuals and patients with malignant diseases, myopathies or renal failure. Clin Chim Acta (1975) 0.75
[Retroviruses and the development of lymphoma]. Onkologie (1987) 0.75
[Risks of a cartilage-bone bank with reference to HIV infection]. HNO (1991) 0.75
GB virus C/hepatitis G virus and intravenous immunoglobulins. Vox Sang (1998) 0.75